Idecabtagene Vicleucel

• Clinical trial with dasatinib for the prevention of CAR-T side effects in patients with relapsed or treatment-resistant multiple myeloma und… Pending
  2023-507537-16-00 Phase I/II 1 country Universitaetsklinikum Wuerzburg AöR
• A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA Recruiting
  2025-521530-28-00 Phase I/II 1 country Universitaetsklinikum Erlangen AöR
• Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector C… Recruiting
  2024-515328-35-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 Phase II/III 17 countries Celgene Corp.
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended
  2022-501346-30-00 Phase III 12 countries Celgene Corp.
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 Phase III 7 countries Celgene Corp.
• A study to assess the efficacy and safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma whi… Ended
  2023-505183-10-00 Phase II 3 countries Celgene Corp.

Showing 1–7 of 7 trials